DK2628115T3 - Insulinudleveringsindretning - Google Patents

Insulinudleveringsindretning Download PDF

Info

Publication number
DK2628115T3
DK2628115T3 DK11833366.5T DK11833366T DK2628115T3 DK 2628115 T3 DK2628115 T3 DK 2628115T3 DK 11833366 T DK11833366 T DK 11833366T DK 2628115 T3 DK2628115 T3 DK 2628115T3
Authority
DK
Denmark
Prior art keywords
zone
control
insulin
mpc
glucose
Prior art date
Application number
DK11833366.5T
Other languages
English (en)
Inventor
Francis J Doyle Iii
Benyamin Grosman
Eyal Dassau
Lois Jovanovic
Howard Zisser
Original Assignee
Univ California
Sansum Diabetes Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Sansum Diabetes Res Inst filed Critical Univ California
Application granted granted Critical
Publication of DK2628115T3 publication Critical patent/DK2628115T3/da

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)

Claims (2)

1. Insulinudleveringsindretning, omfattende et sensorsystem til måling af glukose, en kontrolenhed og et insulinudleveringssystem, hvor glukosesensorsystemet frembringer et sensorsignal, der repræsenterer blodsukkerniveauer og leverer sensorsignalerne til kontrolenheden, hvor kontrolenheden modtager sensorsignalet og frembringer kommandoer, der kommunikeres til insulinudleveringssystemet hvor insulinudleveringssystemet modtager kommandoerne og infunderer insulin i kroppen som reaktion på kommandoerne, kendetegnet ved, at kontrolenheden omfatter en kontrolalgoritme med multi-zonemodelforudsigelse (MPC), der er baseret på fire lokale fordelinger af glykæmi, omfattende hypoglykæmiske, normoglykæmiske, forhøjet glykæmiske og hyper-glykæmiske zoner, hvor kontrolprocesser i den hyperglykæmiske zone, dvs. blodsukkerkoncentration G > 180 mg/dl_, er begrænset til at forebygge overdosering, hvor de fleste kontrolprocesser er implementeret i den forhøjede glykæmiske zone, dvs. 140 < G < 180 mg/dL, hvor kontrolenheden i den normoglykæmiske zone, dvs. 80 < G < 140 mg/dL, er passiv over for afvigelser i glykosemålinger, og hvor det i den hypoglykæmiske zone, dvs. G < 80 mg/dL, er muligt for kontrolenheden at reagere hurtigt på potentiel hypoglykæmi.
2. Insulinudleveringsindretning ifølge krav 1, hvor algoritmen tilvejebringer glykæmizoner og kontrolvægtsforhold (Ok og Rk) ifølge følgende tabel:
DK11833366.5T 2010-10-12 2011-10-12 Insulinudleveringsindretning DK2628115T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39239910P 2010-10-12 2010-10-12
PCT/US2011/056022 WO2012051344A2 (en) 2010-10-12 2011-10-12 Maintaining multiple defined physiological zones using model predictive control

Publications (1)

Publication Number Publication Date
DK2628115T3 true DK2628115T3 (da) 2015-08-24

Family

ID=45938960

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11833366.5T DK2628115T3 (da) 2010-10-12 2011-10-12 Insulinudleveringsindretning

Country Status (8)

Country Link
US (1) US9700708B2 (da)
EP (1) EP2628115B1 (da)
JP (1) JP6062859B2 (da)
CA (1) CA2816388C (da)
DK (1) DK2628115T3 (da)
ES (1) ES2544874T3 (da)
HK (1) HK1182496A1 (da)
WO (1) WO2012051344A2 (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
US9757510B2 (en) 2012-06-29 2017-09-12 Animas Corporation Method and system to handle manual boluses or meal events for closed-loop controllers
US9486578B2 (en) * 2012-12-07 2016-11-08 Animas Corporation Method and system for tuning a closed-loop controller for an artificial pancreas
US9907909B2 (en) 2012-12-20 2018-03-06 Animas Corporation Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas
AU2014205123B2 (en) * 2013-01-14 2018-08-16 The Regents Of University Of California Daily periodic target-zone modulation in the model predictive control problem for artificial pancreas for type 1 diabetes applications
US9795737B2 (en) 2013-03-15 2017-10-24 Animas Corporation Method and system for closed-loop control of an artificial pancreas
EP2973095B1 (en) 2013-03-15 2018-05-09 Animas Corporation Insulin time-action model
US9517306B2 (en) 2013-03-15 2016-12-13 Animas Corporation Method and system for closed-loop control of an artificial pancreas
US9561324B2 (en) 2013-07-19 2017-02-07 Bigfoot Biomedical, Inc. Infusion pump system and method
US9474855B2 (en) 2013-10-04 2016-10-25 Animas Corporation Method and system for controlling a tuning factor due to sensor replacement for closed-loop controller in an artificial pancreas
US9861747B2 (en) 2013-12-05 2018-01-09 Lifescan, Inc. Method and system for management of diabetes with a glucose monitor and infusion pump to provide feedback on bolus dosing
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
CN106714874B (zh) * 2014-08-06 2019-10-08 加利福尼亚大学董事会 用于控制应用的滚动时域状态初始化器
EP4400130A3 (en) 2015-02-18 2024-10-16 Insulet Corporation Fluid delivery and infusion devices
EP3374905A1 (en) 2016-01-13 2018-09-19 Bigfoot Biomedical, Inc. User interface for diabetes management system
WO2017123703A2 (en) 2016-01-14 2017-07-20 Bigfoot Biomedical, Inc. Occlusion resolution in medication delivery devices, systems, and methods
EP3443998A1 (en) * 2016-01-14 2019-02-20 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
FR3047098B1 (fr) * 2016-01-21 2018-05-25 Voluntis Gestion de l'equilibre glycemique d'un patient diabetique
BR112018015910A2 (pt) * 2016-02-05 2018-12-26 Animas Corporation ferramenta de visualização e análise para um sistema de liberação de fármacos
EP3515535A1 (en) 2016-09-23 2019-07-31 Insulet Corporation Fluid delivery device with sensor
CA3037432A1 (en) 2016-12-12 2018-06-21 Bigfoot Biomedical, Inc. Alarms and alerts for medication delivery devices and related systems and methods
US10583250B2 (en) 2017-01-13 2020-03-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
EP3568859A1 (en) 2017-01-13 2019-11-20 Bigfoot Biomedical, Inc. Insulin delivery methods, systems and devices
US10758675B2 (en) 2017-01-13 2020-09-01 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10500334B2 (en) 2017-01-13 2019-12-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
US10881792B2 (en) 2017-01-13 2021-01-05 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
EP3568860A1 (en) 2017-01-13 2019-11-20 Bigfoot Biomedical, Inc. Insulin delivery methods, systems and devices
US11497851B2 (en) 2017-03-31 2022-11-15 Lifescan Ip Holdings, Llc Maintaining maximum dosing limits for closed loop insulin management systems
US10729849B2 (en) 2017-04-07 2020-08-04 LifeSpan IP Holdings, LLC Insulin-on-board accounting in an artificial pancreas system
US11147920B2 (en) 2017-04-18 2021-10-19 Lifescan Ip Holdings, Llc Diabetes management system with automatic basal and manual bolus insulin control
ES2903174T3 (es) 2017-05-05 2022-03-31 Lilly Co Eli Control de bucle cerrado de glucosa fisiológica
EP3438858A1 (en) 2017-08-02 2019-02-06 Diabeloop Closed-loop blood glucose control systems and methods
WO2019125932A1 (en) 2017-12-21 2019-06-27 Eli Lilly And Company Closed loop control of physiological glucose
JP6938363B2 (ja) * 2017-12-27 2021-09-22 オムロンヘルスケア株式会社 情報処理装置、生体情報測定装置、方法及びプログラム
USD928199S1 (en) 2018-04-02 2021-08-17 Bigfoot Biomedical, Inc. Medication delivery device with icons
US11158413B2 (en) * 2018-04-23 2021-10-26 Medtronic Minimed, Inc. Personalized closed loop medication delivery system that utilizes a digital twin of the patient
AU2019263490A1 (en) 2018-05-04 2020-11-26 Insulet Corporation Safety constraints for a control algorithm-based drug delivery system
AU2019288473A1 (en) 2018-06-22 2020-12-10 Ypsomed Ag Insulin and pramlintide delivery systems, methods, and devices
US11628251B2 (en) 2018-09-28 2023-04-18 Insulet Corporation Activity mode for artificial pancreas system
US11565039B2 (en) 2018-10-11 2023-01-31 Insulet Corporation Event detection for drug delivery system
USD920343S1 (en) 2019-01-09 2021-05-25 Bigfoot Biomedical, Inc. Display screen or portion thereof with graphical user interface associated with insulin delivery
US11986629B2 (en) * 2019-06-11 2024-05-21 Medtronic Minimed, Inc. Personalized closed loop optimization systems and methods
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
EP4069082B1 (en) 2019-12-06 2024-06-05 Insulet Corporation Techniques and devices providing adaptivity and personalization in diabetes treatment
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
JP7512395B2 (ja) 2020-01-06 2024-07-08 インスレット コーポレイション 持続する残差に基づく食事および／または運動行為の予測
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11986630B2 (en) 2020-02-12 2024-05-21 Insulet Corporation Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
US12115351B2 (en) 2020-09-30 2024-10-15 Insulet Corporation Secure wireless communications between a glucose monitor and other devices
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
EP4409581A1 (en) 2021-09-27 2024-08-07 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery
US12097355B2 (en) 2023-01-06 2024-09-24 Insulet Corporation Automatically or manually initiated meal bolus delivery with subsequent automatic safety constraint relaxation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3251224B2 (ja) * 1998-02-26 2002-01-28 勲 長澤 病棟情報システム
US8423113B2 (en) * 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US9135402B2 (en) * 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US8369919B2 (en) * 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
JP5037496B2 (ja) * 2005-05-13 2012-09-26 トラスティーズ オブ ボストン ユニバーシティ １型糖尿病用の完全自動制御システム
US9392969B2 (en) * 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US8721584B2 (en) * 2006-11-02 2014-05-13 The University Of North Carolina At Chapel Hill Methods and systems for determining an intravenous insulin infusion rate to correct hyperglycemia of a patient, to maintain euglycemia of a patient, and to prevent hypoglycemia of a patient
US20080154513A1 (en) * 2006-12-21 2008-06-26 University Of Virginia Patent Foundation Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes
CN101663059A (zh) * 2007-03-19 2010-03-03 梅丁格有限公司 药物输送设备中选择单次剂量的用户接口
US8221345B2 (en) * 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
EP2276405A4 (en) * 2008-05-12 2013-10-09 Us Dept Veterans Affairs AUTOMATED SYSTEM AND METHOD FOR DIABETES CONTROL
US9317657B2 (en) * 2008-11-26 2016-04-19 University Of Virginia Patent Foundation Method, system, and computer program product for tracking of blood glucose variability in diabetes
WO2010099313A1 (en) * 2009-02-25 2010-09-02 University Of Virginia Patent Foundation Cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery

Also Published As

Publication number Publication date
HK1182496A1 (en) 2013-11-29
EP2628115B1 (en) 2015-06-03
CA2816388A1 (en) 2012-04-19
WO2012051344A2 (en) 2012-04-19
JP6062859B2 (ja) 2017-01-18
US9700708B2 (en) 2017-07-11
EP2628115A2 (en) 2013-08-21
CA2816388C (en) 2016-12-06
EP2628115A4 (en) 2014-04-23
US20130231642A1 (en) 2013-09-05
JP2013542011A (ja) 2013-11-21
ES2544874T3 (es) 2015-09-04
WO2012051344A3 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
DK2628115T3 (da) Insulinudleveringsindretning
US8762070B2 (en) Systems, devices and methods to deliver biological factors or drugs to a subject
Huyett et al. Design and evaluation of a robust PID controller for a fully implantable artificial pancreas
EP2967450B1 (en) System for closed-loop control of an artificial pancreas
Cobelli et al. Artificial pancreas: past, present, future
Colmegna et al. Reducing Risks in Type 1 Diabetes Using ${\cal H} _\infty $ Control
CA2897925C (en) Daily periodic target-zone modulation in the model predictive control problem for artificial pancreas for type 1 diabetes applications
US20180147349A1 (en) Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas
US20100262117A1 (en) Predictive control based system and method for control of insulin delivery in diabetes using glucose sensing
CN102395310A (zh) 用于自动监控糖尿病相关治疗的方法以及系统
WO2013024044A2 (en) Insulin pump
Grosman et al. Multi-zone-MPC: Clinical inspired control algorithm for the artificial pancreas
Doyle et al. I. Glucose control strategies for treating type 1 diabetes mellitus
CN110352460A (zh) 人工胰腺
Batora et al. Bihormonal control of blood glucose in people with type 1 diabetes
Prud'Homme et al. Preclinically assessed optimal control of postprandial glucose excursions for type 1 patients with diabetes
Incremona et al. Artificial pancreas: from control-to-range to control-to-target
Ata et al. Model based control of artificial pancreas under meal disturbances
Duun-Henriksen et al. Tuning of controller for type 1 diabetes treatment with stochastic differential equations
Csete et al. The mathematician's control toolbox for management of type 1 diabetes
Quiroz et al. Adjustment of sensitive parameters of a mathematical model of glucose metabolism using an evolutionary algorithm
El Hachimi et al. Overcoming control challenges in the artificial pancreas
Yan et al. Predictive-retrospective proportional glycemic control for type 1 diabetes mellitus
Stemmann et al. Diabetic Blood Glucose Control via Optimization over Insulin and Glucose Doses